Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells

Abstract excerpt

Abstract Osimertinib (AZD9291) has an efficacy superior to that of standard EGFR-tyrosine kinase inhibitors for the first-line treatment of patients with EGFR-mutant advanced non–small cell lung cancer (NSCLC). However, patients treated with osimertinib eventually acquire drug resistance, and novel therapeutic strategies to overcome acquired resistance are needed. In clinical or preclinical models, several...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Treatments and Mutations
• Share to Pancreatic and Hepatic Oncology Research
• Share to Phagocytosis and Immune Regulation